Brind.

Indonesian Regulator BPOM Nears Agreement with China on Drug and Food Safety

1 report, 1 independent Updated Sep 20
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The Indonesian Food and Drug Authority (BPOM) is pushing to renew its agreement with the National Medical Products Administration (NMPA), China's counterpart to BPOM. The draft of the renewed Memorandum of Understanding (MoU) is complete and is expected to be signed soon. The MoU seeks to cover various regulations, including medicines, vaccines, biological products, pharmaceutical ingredients, cosmetics, and digital regulatory technology.

From antaranews.com

Why it matters

Some supportBrind's analysis of the reports

The renewed MoU aims to establish a broader framework for international trade and regulatory cooperation between Indonesia and China. BPOM's existing status as a WHO-Listed Authority (WLA) demonstrates strong manufacturing capabilities. The agreement could pave the way for Chinese investment in Indonesian vaccine technology.

From antaranews.com

Who's involved

  • IndonesiaGeopolitical state whose regulatory body is the subject of the agreement.
  • Indonesian Food and Drug AuthorityIndonesian government agency responsible for product regulation and international trade.
  • BeijingLocation where the parties are currently meeting to finalize the agreement.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped